HIV envelope- humoral responses Flashcards
What is the HIV spike composed of?
a trimer of 2xgp120 and gp41
What does viral attachment involve?
interaction of gp120 with CD4 and CCR5/CXCR4
What happens once gp120 binds to CD4?
exposure of coreceptor binding site and the formtion of a triple-strnaded coiled-coil with fusion peptide (gp41) exposure then coreceptor binding
What are the functions of anti-HIV-1 antibody in mucosal tissues?
target cell free infection; ADCC-mediated inhibition; targeting of cellular receptor/coreceptor
What is neutralisation defined as?
ability of natibodies to reduce virus infectivity by interfering at steps in viral life cycle
How do neutralising antibodies work?
prevent cell free infection and spread of infection via cell-to-cell transmission
What is the presence of NAbs correlated to?
most constant correlate of immune protection against viral infections
What is the function of Nabs in HIV vaccination?
essential for successful HIV vaccine but might not be sufficient against HIV
What is the function of the b12 antibody?
binds to gp120 blocking binding to CD4
What is the function of non-NAbs?
don’t bind to an epitope blocking binding but activate complement via Fc and bind to Fc receptors to work with innate effector cells
How can non-Nabs inhibit cell-to-cell transmission?
through their FCyR-mediated inhibitory activity
How may non-NAbs enhance infection?
trapping of antibody and complement opsonised HIV in follicular DCs acts as HIV reservoir
What makes HIV neutralisation difficult?
only one functional spike is needed for entry so complete AB occupancy of spikes is needed; some epitopes are momentarily exposed; size of Ig can sterically hinder Ab binding to some epitopes; conformational masking of epitopes; antigenic variability ; not many spikes
What is the different between the spikes recognised by Nab and non-Nab?
NAbs recognised functional spikes whereas non-Nabs recognse non-functional spikes
what is the function of non-functional env?
molecular decoy
What prevents antibody recognition of spikes?
glycan shield
What is found in the sera of elite controllers of HIV?
broadly neutralising antibodies
What do the serum levels of NAbs correlate with?
protection and lower viral load
What was seen in passive transfer studies of bNAbs ?
in macaques- give n prior to infection: most animals were protected but needed large doses, in those that did become infected, peak viraemia was lower. in humans- infusion can delay viral rebound during treatment holidays
What type of epitope is suitable for a bNAb?
broadly conserved, exposed epitopes
Why do bNAbs have long CDRH3 loops?
to access hidden epitopes
Why do bNAbs have high levels of somatic mutations?
mutating env proteins
What is the structure of gp120?
heavily glycosylated; composed of 5 constant regions interspersed with 5 variable regions
How much of the molecular weight of gp120 is the glycosylation?
40-50%
Where are hte conserved regions of gp120 found?
at the core
Where are the variable regions of gp120 found?
except V5, they form 4 loops which emanates from the surface of the protein
Where do the neutralising epitopres of gp120 cluster?
form a surface named the neutralising face which is exposed and conerved
Where do the non-neutralising epitopes of gp120 cluster?
non-neutralising face which forms the inner domain of the gp120 core and is realtively conserved
What do the silent face and variable loops correlate to in terms of antibody resposne?
a large fraction of the gp120 surface that is protected against antibody responses by a dense array of carbohydrates and by the capacity of variation
What are neutrailsing targets in gp120?
CD4bs; CD4-induced epitopes; 2G12 epitope (binds glycans on the silent face of gp120); V3 loop
Why are there no antibodies made to the extensive glycosylation?
recognised as self
How does the quarternary structure of env help immune evasion?
two-receptor entry mechanism; occlusion of vulenrable epitopes within trimer; surface variable loops cover conserved elemetns- continous mutation acts as immune decoy; extensive glycosylation occludes most ab epitopes
How much affinity maturation is shown by VRC01- a bNAb?
very high degree- v genes differ by 30%, mutated back to germline, there is little/no bidning of gp120
How does reverse vaccinology work?
isolate bNAbs then design antigen using molecular characterisation of antibody-pathogen-antigen interaction and then create vaccine
What is IC50?
concentration needed to stop 50% of infection
How does HIV evade complement mediated lysis?
incorporates completement regulatory proteins into viral membranes as it buds from the host cell, factor H binds directly to gp120/41
What is complement-mediated Ab-dependent enhancement?
infectivity of HIV opsonised with Ab and complement can be increased when complement receptors are expressed on target cells
Which complement receptor is particularly implicated in complement-mediated Ab-dependent enhancement?
CR2
How does complement-mediated Ab-dependent enhancement work?
increasing adhesion of virion to target cell allowing more efficient engagement with CD4
What is Ab-dependent cellular cytotoxicity?
a complex bewteen the IgG Fab portion of antibody bound to envelope protein on the cell surface and the Fc portion to Fc receptors on effetor cells leads to lysis of the infected cell
What is Ab-dependent cell-mediated viral inhibition?
measure the effects of ADCC-mediated cell killing, which leads to reduced virus production as well as virus inhibition by antiviral cyokines and other secondary effects of FcR-vius interactions eg phagocytosis
What IgA response is seen in plasma and mucosal fluids within weeks of transmission?
anti-gp41 but not anti-gp120
What happens to the concentrations of IgA anti-HIV response?
intiial mucosal response rapidly declines
How may IgA stop viral transfer across mucosal surfaces?
dimeric IgA can aggregate virus impeding viral transfer
What are the potential roles of IgA in HIV infection?
deleterious effect by competing with potential IgG protective Abs or significant protective effect by limiting HIV transmission at the mucosal site